Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer.
Paik ES, Kim TH, Cho YJ, Ryu J, Choi JJ, Lee YY, Kim TJ, Choi CH, Kim WY, Sa JK, Lee JK, Kim BG, Bae DS, Han HD, Ahn HJ, Lee JW.
Paik ES, et al. Among authors: bae ds.
Sci Rep. 2020 Mar 17;10(1):4904. doi: 10.1038/s41598-020-61871-w.
Sci Rep. 2020.
PMID: 32184452
Free PMC article.